Blue Owl discloses 5.92% stake in Aktis Oncology (AKTS) in Schedule 13G

Rhea-AI Filing Summary

Aktis Oncology, Inc. Schedule 13G shows Blue Owl Capital Holdings LP reports beneficial ownership of 3,161,348 shares of common stock, representing 5.92% of the class. The percentage is calculated from March 10, 2026 outstanding shares of 53,403,173, as disclosed in the issuer's 10-K.

Insights

Institutional Ownership Analyst

Large investment firm discloses a 5.92% stake in Aktis Oncology.

Blue Owl Capital Holdings LP reports 3,161,348 shares, equal to 5.92% of the outstanding common stock using the issuer's March 10, 2026 share count. The filing is a passive ownership disclosure under Schedule 13G.

Position size is notable for monitoring potential future disclosures; subsequent filings would show changes in ownership or shifts to active status if they occur.

Key Figures

Shares owned: 3,161,348 shares Percent of class: 5.92% Shares outstanding: 53,403,173 shares

3 metrics

Shares owned 3,161,348 shares Beneficial ownership reported by Blue Owl Capital Holdings

Percent of class 5.92% Calculated using shares outstanding as of <date>March 10, 2026</date>

Shares outstanding 53,403,173 shares Issuer's outstanding common stock as reported in the 10-K (as of <date>March 10, 2026</date>)

Key Terms

Schedule 13G, beneficial ownership, Rule 13d-4

3 terms

Schedule 13G regulatory

"This statement is filed by Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person.""

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficial ownership financial

"Amount beneficially owned: See response to row 9 on the cover page."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Rule 13d-4 regulatory

"Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:36 PM Learn about SEC filing dates

FAQ

What stake does Blue Owl Capital Holdings report in Aktis Oncology (AKTS)?

Blue Owl reports beneficial ownership of 3,161,348 shares, equal to 5.92% of Aktis common stock based on the issuer's March 10, 2026 outstanding share count of 53,403,173.

What filing did Blue Owl use to disclose its position in AKTS?

Blue Owl filed a Schedule 13G statement, which is a passive investor disclosure under Section 13(d) that reports ownership without asserting control or active intent.

How is the reported 5.92% ownership calculated?

The percentage is calculated using the issuer's reported common shares outstanding of 53,403,173 as of March 10, 2026, as cited in the company's 10-K filed on March 30, 2026.

Does this Schedule 13G indicate Blue Owl will seek control of Aktis Oncology?

A Schedule 13G filing indicates a passive ownership reporting status; it does not itself assert plans to seek control or active involvement in company management.

When was the Schedule 13G signed for the Blue Owl disclosure?

The Schedule 13G was signed by Karen Hager, Chief Compliance Officer on May 13, 2026, certifying the reported ownership figures.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aktis Oncology, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

01021M104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 01021M104

1

Names of Reporting Persons

Blue Owl Capital Holdings LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,161,348.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,161,348.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,161,348.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.92 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reported percentage is calculated based on 53,403,173 shares of Common Stock outstanding as of March 10, 2026, as reported on the Issuer's 10-K filed with the Securities and Exchange Commission on March 30, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aktis Oncology, Inc.
(b)	Address of issuer's principal executive offices: 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210
Item 2.
(a)	Name of person filing: This statement is filed by Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."
(b)	Address or principal business office or, if none, residence: 399 Park Avenue, New York, New York 10022
(c)	Citizenship: See response to row 4 on the cover page.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 01021M104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to row 9 on the cover page. Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose.
(b)	Percent of class: See response to row 11 on the cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to row 5 on the cover page.
	(ii) Shared power to vote or to direct the vote: See response to row 6 on the cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to row 7 on the cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to row 8 on the cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blue Owl Capital Holdings LP

Signature:	/s/ Karen Hager
Name/Title:	Karen Hager / Chief Compliance Officer
Date:	05/13/2026